摘要
目的：探讨异甘草酸镁对原发性肝癌肝动脉化疗栓塞术后肝脏的保护作用。方法选择原发性肝癌肝动脉化疗栓塞术患者68例作为研究对象，将其分为异甘草酸镁组和对照组，所有患者均在术前7 d到术后3 d 常规给予保肝药物治疗，异甘草酸镁组在保肝治疗的基础上给予异甘草酸镁治疗，检测并比较两组肝癌患者手术前后肝谷丙转氨酶、谷草转氨酶、总胆红素、总蛋白、白蛋白和胆碱酯酶水平。结果对照组术后3 d 的谷丙转氨酶、谷草转氨酶[（60．2±25．8）IU ／L、（71．5±29．6）IU ／L]均较术前升高[（34．7±18.6）IU ／L、（49．5±20．4）IU ／L]（t ＝7．264、5．974，均 P ＜0．05），异甘草酸镁组术后3 d 的肝损伤指标谷丙转氨酶、谷草转氨酶与术前差异无统计学意义（P ＞0．05）；异甘草酸镁组术前谷丙转氨酶、谷草转氨酶和总胆红素与对照组差异无统计学意义（P ＞0．05），异甘草酸镁组术后3 d 谷丙转氨酶、谷草转氨酶[（44．8±22．8）IU ／L、（57．3±24．8）IU ／L]均明显低于对照组[（60．2±25．8）IU ／L、（71．5±29．6）IU ／L]（t ＝6．385、7.358，均 P ＜0．05）。异甘草酸镁组和对照组术后3 d 的白蛋白和胆碱酯酶[（28．4±4．7）g／L、（8．0±4．8）kU ／L 比（29．3±3．5）g／L、（6．9±4．3）kU ／L]均较术前降低[（34．2±4．3）g／L、（9．3±5．4）kU ／L 比（33．7±3.9）g／L、（9．0±5．8）kU ／L]（t ＝11．834、6．247、10．276、8．743，均 P ＜0．05），异甘草酸镁组术前白蛋白和胆碱酯酶与对照组差异无统计学意义（P ＞0．05），异甘草酸镁组术后3 d 白蛋白和胆碱酯酶[（28．4±4．7）g／L、（8．0±4．8）kU ／L]均明显高于对照组[（29．3±3．5）g／L、（6．9±4．3）kU ／L]（t ＝8．436、6．947，均 P ＜0.05）。异甘草酸镁组不良反应发生率（上腹痛发生率为35．3％，发热发生率为29．4％，恶心呕吐发生率为52.9％）低于对照组（上腹痛发生率55．9％，发热发生率88．2％，恶心呕吐发生率为76．5％）（χ2＝7．246、6.472、6.274，均 P ＜0．05）。结论肝动脉化疗栓塞术对肝癌患者的肝功能有一定的损伤，异甘草酸镁可以减轻肝脏损害，提高肝脏合成功能，对肝脏有一定的保护作用。
Objective To investigate the protective effect of magnesium isoglycyrrhizinate on the liver of hepatic arterial chemoembolization.Methods 68 patients with hepatic arterial chemoembolization were selected as research subjects,they were divided into magnesium isoglycyrrhizinate group and control group.All patients were routinely given hepatoprotective drug treatment from seven days before surgery until three days after surgery,magnesium isoglycyrrhizinate group was given magnesium isoglycyrrhizinate treatment on the basis of hepatoprotective treatment. Detected and compared the alanine aminotransferase,aspartate aminotransferase,total bilirubin,total protein,albumin and cholinesterase levels before and after liver cancer before and after surgery.Results The alanine aminotrans-ferase,aspartate aminotransferase levels at 3 days after surgery[（60.2 ±25.8）and （71.5 ±29.6）IU /L]were higher than before surgery in the control group[（34.7 ±18.6）and （49.5 ±20.4）IU /L]（t =7.264 and 5.974,all P 〈0.05）.The alanine aminotransferase,aspartate aminotransferase levels at 3 days after surgery had no differences with before surgery in the magnesium isoglycyrrhizinate group （P 〉0.05）.The alanine aminotransferase,aspartate amin-otransferase and total bilirubin levels before surgery in magnesium isoglycyrrhizinate group had no differences with the control group （P 〉0.05）.The alanine aminotransferase,aspartate aminotransferase levels at 3 days after surgery in the magnesium isoglycyrrhizinate group[（44.8 ±22.8）and （57.3 ±24.8）IU /L]were higher than those in the control group[（60.2 ±25.8）and （71.5 ±29.6）IU /L]（t =6.385 and 7.358,all P 〈0.05）.The albumin and cholinesterase levels at 3 days after surgery in the magnesium isoglycyrrhizinate group and the control group[（28.4 ± 4.7）g/L,（8.0 ±4.8）kU /L and （29.3 ±3.5）g/L,（6.9 ±4.3）kU /L]were lower than before surgery[（34.2 ± 4.3）g/L,（9.3 ±5.4）kU /L and （33.7 ±3.9）g/L,（9.0 ±5.8）kU /L]（t =11.834,6.247 and 10.276,8.743,all P 〈0.05）.The albumin and cholinesterase levels before surgery in the magnesium isoglycyrrhizinate group had no differences with the control group （P 〉0.05）.The albumin and cholinesterase levels at 3 days after surgery in the magnesium isoglycyrrhizinate group[（28.4 ±4.7）g/L,（8.0 ±4.8）kU /L]were lower than those of control group [（29.3 ±3.5 ）g/L,（6.9 ±4.3）kU /L]（t =8.436 and 6.947,all P 〈0.05 ）.The incidence rates of adverse reactions of the magnesium isoglycyrrhizinate group （upper abdominal pain incidence rate was 35.3%,fever incidence rate was 29.4%,nausea and vomiting incidence rate was 52.9%）were lower than those of the control group（55.9%,88.2%,76.5%）（χ2 =7.246,6.472,6.274,all P 〈0.05）.Conclusion Hepatic arterial chemoem-bolization has some damage to liver function of liver cancer patients.Magnesium isoglycyrrhizinate can reduce liver damage,improve liver synthetic function,and has a protective effect on liver.
出处
《中国基层医药》
CAS
2016年第19期2885-2889,共5页
Chinese Journal of Primary Medicine and Pharmacy
关键词
异甘草酸镁
原发性肝癌
肝动脉化疗栓塞术
肝功能
Magnesium isoglycyrrhizinate
Primary liver cancer
Transcatheter arterial chemoemboliza-tion
Hepatic function
